Cardiovascular Disease Prevention in Men with Vascular Erectile Dysfunction: The View of the Preventive Cardiologist

Nishant P Shah1, Miguel Cainzos-Achirica2, David I Feldman1

  • 1Ciccarone Center for the Prevention of Heart Disease, Department of Cardiology, Johns Hopkins Medical Institutions, Baltimore, Md.

Insights

Vascular erectile dysfunction signals higher cardiovascular risk. This review proposes integrating erectile dysfunction evaluation with personalized tools like coronary artery calcium scoring for better cardiovascular risk assessment and management.

Area of Science:

  • Cardiology
  • Urology
  • Preventive Medicine

Background:

  • Vascular erectile dysfunction (VED) is a significant indicator of underlying cardiovascular disease (CVD).
  • Current cardiovascular risk assessment guidelines lack specific recommendations for evaluating VED.
  • There is a growing consensus among experts for more defined guidance on VED assessment in cardiovascular risk stratification.

Purpose of the Study:

  • To provide a preventive cardiologist's perspective on the role of VED evaluation in cardiovascular risk assessment.
  • To discuss limitations of existing risk scores and the utility of personalized prognostic tools for men with VED.
  • To propose an integrated approach for cardiovascular risk stratification and management in patients with VED.

Main Methods:

  • Review of current literature and guidelines regarding VED and cardiovascular risk.
  • Analysis of the interplay between VED assessment and personalized prognostic tools (e.g., coronary artery calcium score).
  • Development of a clinical decision-making algorithm for healthcare providers.

Main Results:

  • Existing risk scores have limitations in fully capturing cardiovascular risk in men with VED.
  • Personalized prognostic tools, such as coronary artery calcium scoring, offer valuable insights beyond traditional risk factors.
  • Stress testing is considered a primary tool, with others as second-line options for risk stratification in VED patients.

Conclusions:

  • Integrating VED assessment into cardiovascular risk stratification is crucial.
  • Personalized prognostic tools can enhance the accuracy of risk assessment and guide management strategies for men with VED.
  • A collaborative approach involving primary care, urology, and cardiology is recommended for optimal patient care.

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.4K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
851
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
737
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
582
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
569
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K